Eligibility Module

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module

Ignite Creation Date: 2025-12-25 @ 4:12 AM
Ignite Modification Date: 2025-12-25 @ 4:12 AM
NCT ID: NCT01602120
Eligibility Criteria: Inclusion Criteria: * For CFD4870g participants: Previous enrollment and completion (Month 18 visit) of Study CFD4870g without early treatment discontinuation (lampalizumab or sham) * For GX29455 participants: Previous enrollment and completion (Week 24 visit) of Study GX29455 without early treatment discontinuation (lampalizumab or sham) * Sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit quality fundus imaging Exclusion Criteria: * Early treatment and/or study discontinuation prior to completion of study CFD4870g (GX01456) and GX29455 * Vitrectomy surgery, submacular surgery, or other surgical intervention for age-related macular degeneration (AMD) in the study eye * Subfoveal focal laser photocoagulation in the study eye * Treatment with Visodyne, external-beam radiation therapy, or transpupillary thermotherapy in the study eye * Intravitreally (ITV) drug delivery (e.g., ITV corticosteroid injection, anti-angiogenic drugs, anticomplement drugs, or device implantation) in the study eye. Lampalizumab in study eye and ranibizumab in either eye are permitted * Any concurrent ocular or intraocular condition in the study eye that contraindicates the use of an investigational drug or may affect interpretation of the study results or may render the participant at high risk for treatment complications
Healthy Volunteers: False
Sex: ALL
Minimum Age: 60 Years
Maximum Age: 89 Years
Study: NCT01602120
Study Brief:
Protocol Section: NCT01602120